VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

AbbVie Inc. vs DexCom, Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

AbbVie Inc.

ABBV · New York Stock Exchange

Market cap (USD)$355.5B
Gross margin (TTM)70.2%
Operating margin (TTM)26.7%
Net margin (TTM)6.9%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2026-01-11
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into AbbVie Inc.'s moat claims, evidence, and risks.

View ABBV analysis

DexCom, Inc.

DXCM · Nasdaq Global Select Market

Market cap (USD)$23.6B
Gross margin (TTM)60.1%
Operating margin (TTM)19.6%
Net margin (TTM)17.9%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2026-04-24
Moat score
82/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into DexCom, Inc.'s moat claims, evidence, and risks.

View DXCM analysis

Comparison highlights

  • Moat score gap: DexCom, Inc. leads (82 / 100 vs 65 / 100 for AbbVie Inc.).
  • Segment focus: AbbVie Inc. has 6 segments (47.4% in Immunology); DexCom, Inc. has 1 segment (100% in Continuous glucose monitoring systems).
  • Moat breadth: AbbVie Inc. has 3 moat types across 2 domains; DexCom, Inc. has 5 across 3.

Primary market context

AbbVie Inc.

Immunology

Market

Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)

Geography

Global

Customer

Prescribing specialists (rheumatology, dermatology, gastroenterology), payers (PBMs/insurers), patients

Role

Innovator biopharma (R&D, clinical development, regulated manufacturing, commercialization)

Revenue share

47.4%

DexCom, Inc.

Continuous glucose monitoring systems

Market

Global continuous glucose monitoring systems and glucose biosensing devices

Geography

Global, with FY2025 revenue 71.5% United States and 28.5% international

Customer

People with diabetes, metabolic-health users, caregivers, clinicians, payors, distributors and pharmacy channels

Role

CGM device manufacturer, disposable sensor supplier, software/data platform and distribution partner

Revenue share

100%

Side-by-side metrics

AbbVie Inc.
DexCom, Inc.
Ticker / Exchange
ABBV - New York Stock Exchange
DXCM - Nasdaq Global Select Market
Market cap (USD)
$355.5B
$23.6B
Gross margin (TTM)
70.2%
60.1%
Operating margin (TTM)
26.7%
19.6%
Net margin (TTM)
6.9%
17.9%
Sector
Healthcare
Healthcare
Industry
Drug Manufacturers - General
Medical - Devices
HQ country
US
US
Primary segment
Immunology
Continuous glucose monitoring systems
Market structure
Oligopoly
Oligopoly
Market share
n/a
35.1% (estimated)
HHI estimate
n/a
4,452
Pricing power
Moderate
Moderate
Moat score
65 / 100
82 / 100
Moat domains
Legal, Demand
Demand, Network, Legal
Last update
2026-01-11
2026-04-24

Moat coverage

Shared moat types

Regulated Standards PipeBrand Trust

AbbVie Inc. strengths

IP Choke Point

DexCom, Inc. strengths

Installed Base ConsumablesEcosystem ComplementsData Workflow Lockin

Segment mix

AbbVie Inc. segments

Full profile >

Immunology

Oligopoly

47.4%

Oncology

Competitive

11.6%

Neuroscience

Competitive

16%

Aesthetics

Oligopoly

9.2%

Eye Care

Competitive

4%

Other Key Products

Competitive

11.9%

DexCom, Inc. segments

Full profile >

Continuous glucose monitoring systems

Oligopoly

100%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.